文献速递结核与非结核分枝杆菌艾滋病与性传播感染细菌感染、耐药与抗菌药物

高HIV-1与结核共流行地区利福平敏感肺结核获得性异烟肼和利福平耐药发生率低

Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence.
PubMed 文献 · J Infect Dis · 2017-01-01

在南非Khayelitsha高HIV-1与结核共流行区招募306例利福平敏感肺结核患者,治疗期间随访发现获得性耐药发生率约0.3%–1%,基线异烟肼单耐药6.1%但无扩增耐药,标准化每日方案、高抗逆转录病毒治疗覆盖及低异烟肼单耐药与低获得性耐药相关。

要点

  • 利福平敏感肺结核中获得性耐药发生率低,约0.3%–1%。
  • 基线异烟肼单耐药6.1%,但随访中未见扩增耐药。
  • 标准化每日方案和高ART覆盖与低获得性耐药相关。

核心结论

  • 标准化每日抗结核方案、高抗逆转录病毒治疗覆盖率及低异烟肼单耐药率与低获得性耐药频率相关。

研究设计与样本

  • 在南非Khayelitsha招募GeneXpert MTB/RIF确认的利福平敏感肺结核患者306例,其中62%合并HIV-1感染。
  • 在治疗2个月和5–6个月进行液体培养和依从性评估,对培养阳性菌株行MTBDRplus检测以获得性耐药。
  • 采用间隔区寡核苷酸分型和全基因组测序判断基线分离株与获得性耐药分离株的同源性,并回顾性检测基线异烟肼单耐药。

主要发现

  • 284例结局确定完整,其中5例在治疗期间或之后获得耐药结核分枝杆菌菌株。
  • 1株确认获得性耐药,2株确认为外源性再感染,2株无法恢复用于基因分型。
  • 279株基线分离株中17株(6.1%;95%CI 3.6%–9.6%)为异烟肼单耐药,其中13株携带inhA启动子突变,但17株中0株出现扩增耐药。

临床怎么用

  • 在高HIV-1与结核共流行地区,对利福平敏感肺结核采用标准化每日方案并提高ART覆盖可能有助于限制获得性耐药。
  • 基线异烟肼单耐药常见但扩增耐药少见,提示需关注但不必过度担忧获得性耐药。

局限性

  • 5例获得耐药菌株中2例无法恢复用于基因分型,可能影响获得性耐药归因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We estimated the incidence of acquired isoniazid and rifampicin resistance in rifampicin-susceptible tuberculosis in a setting of high human immunodeficiency virus type 1 (HIV-1) infection and tuberculosis coprevalence. METHODS: GeneXpert MTB/RIF-confirmed patients with rifampicin-susceptible tuberculosis were recruited at antituberculosis treatment initiation in Khayelitsha, South Africa. Liquid culture and adherence assessment were performed at 2 and 5-6 months. MTBDRplus was performed on mycobacteria-positive cultures to ascertain acquired drug resistance (ADR). Spoligotyping and whole-genome sequencing were performed to ascertain homogeneity between baseline isolates and isolates with ADR. Baseline isolates were retrospectively tested for isoniazid monoresistance. An electronic database review was performed to ascertain tuberculosis recurrences. RESULTS: A total of 306 participants (62% with HIV-1 coinfection, of whom 71% received antiretroviral therapy) were recruited. Ascertainment of outcomes was complete for 284 participants. Five acquired a resistant Mycobacterium tuberculosis strain during or subsequent to treatment. One strain was confirmed to have ADR, 2 were confirmed as causing exogenous reinfection, and 2 were unrecoverable for genotyping. Incident ADR was estimated to have ranged from 0.3% (95% confidence interval [CI], .1%-1.9%; 1 of 284 participants) to 1% (95% CI, .2%-3%; 3 of 284 participants). Seventeen of 279 baseline isolates (6.1%; 95% CI, 3.6%-9.6%) had isoniazid monoresistance (13 of 17 had an inhA promoter mutation), but 0 of 17 had amplified resistance. CONCLUSIONS: Treatment with standardized antituberculosis regimens dosed daily throughout, high uptake of antiretroviral therapy, and low prevalence of isoniazid monoresistance were associated with a low frequency of ADR.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rockwood N, Sirgel F, Streicher E, et al. Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence. J Infect Dis. 2017. PMID: 28934422. doi:10.1093/infdis/jix337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。